Aav cardiac gene therapy for cardiomyopathy
AssigneeUniversity of Florida Research Foundation, Inc.
InventorsHugh Lee Sweeney, Margaret Mary Sleeper
Life of this patent
Estimating the term…
Abstract
The present invention is related to compositions and methods useful in treating heart conditions. The disclosed compositions and methods are based on an AAV therapy comprising a recombinant AAV vector for delivering two or more transgenes into the heart of a subject, wherein the transgenes comprise an S100 family protein and an apoptotic inhibitor. In some aspects, targeting multiple sources of one or more heart conditions can provide synergistic benefits during treatment.
Claims25
A recombinant adeno-associated virus (rAAV) nucleic acid vector for delivering two or more transgenes into the heart of a subject, wherein said vector comprises, from 5′ to 3′, in order, a first adeno-associated virus (AAV) inverted terminal repeat (ITR) sequence, two or more transgenes and a promoter operably linked to the two or more transgenes, a polyadenylation signal, and a second AAV inverted terminal repeat (ITR) sequence, wherein the two or more transgenes comprise an S100 family protein and an apoptotic inhibitor.
Dependencies are inferred from the claim text.